Market News & Trends
NGM Bio’s NGM621 Receives Fast-Track Designation for the Treatment of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NGM Biopharmaceuticals, Inc. recently announced the US FDA has granted Fast-Track designation to NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3, for the treatment of….
Entasis Therapeutics Receives Acquisition Proposal From Existing Majority Stockholder Innoviva Inc.
Entasis Therapeutics Holdings Inc. recently announced its Board of Directors received a preliminary, non-binding proposal from its majority stockholder Innoviva, Inc. to acquire all….
Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the US & Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Immunic, Inc. recently announced the company received a Notice of Allowance from the USPTO for patent application 16/644581 titled IL-17 and IFN-gamma inhibition for the…
ImCheck Announces First Patients Dosed in Phase 2 of EVICTION Trial for ICT01
ImCheck Therapeutics recently announced the first patients have been dosed in the Phase 2a monotherapy expansion arm in the ongoing Phase 1/2a EVICTION clinical trial…
Pardes Biosciences Announces FDA Clearance of IND Application for Oral Antiviral Drug Candidate for the Treatment & Prevention of SARS-CoV-2 Infections
Pardes Biosciences, Inc. recently announced its Investigational New Drug (IND) application for PBI-0451 has been cleared by the US FDA. “As we enter our third…
Arch Scientists Publish Data on the Mechanism of Action & Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury
Arch Biopartners Inc. recently announced a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper…
Pharmazz Inc. Submits INDA to India Central Drugs Standard Control Organization for Phase 2 Clinical Trial of Sovateltide in Hypoxic-Ischemic Encephalopathy in Neonates
Pharmazz, Inc. recently announced it has submitted an Investigational New Drug Application (INDA) to the India Central Drugs Standard Control Organization (CDSCO) for a Phase…
Regio Biosciences Enters License Agreement With AstraZeneca for Phase 2a Asset in Peripheral Artery Disease
Regio Biosciences, a Hibiscus BioVentures company, recently announced it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic…
Silo Pharma Extends Exclusive Option Agreement for Homing Peptides
Silo Pharma, Inc. recently announced it has extended its exclusive option agreement with the University of Maryland, Baltimore, to explore a novel invention generally known as….
CordenPharma Completes Acquisition of Three Manufacturing Facilities From Vifor Pharma
CordenPharma recently announced the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. (including its…
Nashville Biosciences Collaborates With Datavant to Accelerate Life Sciences Drug Discovery & Clinical Research
Nashville Biosciences and Datavant recently announced a collaboration that will enable biopharma companies to connect their trial data to research datasets from BioVU. The linkages…
Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis & Secures $175 Million Credit Facility
Tarsus Pharmaceuticals, Inc. recently announced it has completed enrollment of Saturn-2, the company’s second pivotal Phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) for patients with….
Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune & Inflammatory Diseases from Carna Biosciences
Brickell Biotech, Inc. and Carna Biosciences, Inc. recently announced they have entered into a licensing agreement, whereby Brickell will have the exclusive, worldwide rights to develop and commercialize….
Evoke Pharma & EVERSANA Extend Commercialization Partnership to Further Support GIMOTI
Evoke Pharma, Inc. and EVERSANA Life Science Services, LLC recently announced the extension of their agreement to continue collaborating on the commercialization and distribution of….
QSAM Biosciences Receives Rare Pediatric Disease Designation From FDA for CycloSam in the Treatment of Osteosarcoma
QSAM Biosciences Inc. recently announced the US FDA has granted Rare Pediatric Disease Designation to QSAM’s clinical-stage drug candidate, CycloSam, for the treatment osteosarcoma, a…
PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA in Advanced Head & Neck Cancer
PDS Biotechnology Corporation recently announced its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus (HPV)-associated head and neck cancer achieved its preliminary objective…
Syner-G BioPharma Group Acquires IMPACT; Expands Services for Biotech & Pharma Copanies
Syner-G BioPharma Group recently announced the acquisition of Impact Pharmaceutical Services (IMPACT). Based in Research Triangle Park, NC, IMPACT supports the….
MaxCyte Signs Strategic Platform License With Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
MaxCyte, Inc. recently announced the signing of a strategic platform license (SPL) with Intima Bioscience, Inc., a clinical stage biotechnology company developing genetically engineered cell….
Polyplus Acquires e-Zyvec to Expand Expertise in Plasmid DNA Vector Engineering
Polyplus recently announced the acquisition of e-Zyvec, a provider of DNA design and production services for tailor-made DNA vectors for gene therapy, bio-manufacturing, and research.…
ANAVEX2-73 (Blarcamesine) AVATAR Phase 3 Trial Met Primary & Secondary Efficacy Endpoints for the Treatment of Adult Patients With Rett Syndrome
Anavex Life Sciences Corp. recently reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female….
